From Symptoms to Solutions : Leeway Marketplace

1. FGFR inhibitors are the most appropriate option for patients with refractory myelofibrosis in which setting?

Patients harboring FGFR fusions or rearrangements.

Patients who are post-splenectomy.

Patients awaiting hematopoietic stem cell transplantation.

Patients with anemia.

2. What is the most appropriate second-line option for symptom and spleen management following ruxolitinib failure in patients with myelofibrosis?

Hematopoietic stem cell transplantation.

Erythropoiesis-stimulating agents.

Steroids

An alternative JAK inhibitor

3. A medication in which therapeutic class was the first to be approved for myelofibrosis?

Androgens and corticosteroids

Fibroblast growth factor receptor (FGFR) inhibitors

Vascular endothelial growth factor inhibitors

Janus kinase (JAK) inhibitors

4. When is splenectomy considered the most appropriate treatment option for patients with myelofibrosis?

In any patient with myelofibrosis.

In preparation for hematopoietic stem cell transplantation.

In the presence of massive splenomegaly.

In those who require infrequent red blood cell transfusions.

5. In what setting is allogeneic hematopoietic stem cell transplantation most appropriate for patients with primary myelofibrosis?

Patients with intermediate-1 disease without poor prognosis factors.

Patients with low disease risk but who are symptomatic.

Patients with intermediate-1 disease and poor prognosis factors.

Patients > 65 years of age.

Question 1 of 5

Leeway Marketplace